PacificGMP and Vasgene Therapeutics have successfully completed the large-scale cGMP manufacture of Vasgene’s recombinant fusion protein for use in a Phase I trial. “Using our 500-liter capacity Wave bioreactor platform, we produced and subsequently purified enough of Vasgene’s recombinant fusion protein to aseptically fill more than 2,500 vials,” said Kristin DeFife, vice president of operations at PacificGMP. “We worked very closely with the scientists at Vasgene and welcomed their...